



Stabilis



Norepinephrine bitartrate



Noms commerciaux

Adine	Chili
Arterenol	Allemagne
Biemefrin	Turquie
Boguefren	Mexique
Cardenor	Turquie
Cardiamed	Malaisie
Drenorep	Pérou
Epinor	Inde
Fioritina	Argentine
Hyponor	Brésil
Levonor	Pologne
Levophed	Arabie Saoudite, Belgique, Canada, Chili, Emirats Arabes Unis, Etats Unis d'Amérique, Luxembourg, Malaisie, Nouvelle Zélande
Levophrine	Egypte
Nadrin	Inde
Naretia	Mexique
Nepridar	Mexique
Noradren	Pérou
Noradrenalin	Norvège
Noradrenaline	France, Grande Bretagne, Irlande, Roumanie, Suisse, Tunisie
Norages	Espagne
Norepine	Belgique
Pridam	Chili, Mexique
Radrenit	Mexique
Softamicid	Mexique
Steradine	Turquie
Tehipren	Mexique



Stabilité des solutions

PVC			0,004 & 0,008 mg/ml	25°C		24			642
PVC			0,064 mg/ml	4°C		61			3111
PVC			0,016 & 0,04 mg/ml	5°C		30			197

		0,064 mg/ml	23°C		24			192
		0.01 mg/ml	2-8°C		90			4323
		0.1 mg/ml	2-8°C		7			3346
		0.1 mg/ml	2-8°C		90			4323
		0.2 mg/ml	-20°C		365			3989
		0.2 mg/ml	5°C		365			3989
		0,5 mg/ml	20-25°C		48			4250
		1,16 mg/ml	20-25°C		48			4250
		0.2 mg/ml	-20°C		365			3989
		0.2 mg/ml	5°C		365			3989
		0,064 mg/ml	22-23°C		24			4758



Stabilité en mélange

		0,06 mg/ml	22°C		Dopamine hydrochloride : 5 mg/ml	24		3381
		0,06 mg/ml	22°C		Dobutamine hydrochloride : 5 mg/ml	24		3381
		0,06 mg/ml	22°C		Dobutamine hydrochloride : 5 mg/ml Amiodarone hydrochloride : 12,5 mg/ml	24		3381
		0,03 mg/ml	22°C-23°C		Milrinone lactate : 0,2 mg/ml	4		813
		0,032 mg/ml	25°C		Levofloxacin : 2,5 mg/ml	4		3865
		0,032 mg/ml	25°C		Moxifloxacin : 0,8 mg/ml	4		3865
		0,004 mg/ml	?		Ranitidine hydrochloride : 2 mg/ml	4		210
		0,008 mg/ml	?		Ranitidine hydrochloride : 2 mg/ml	12		210
		0,004 & 0,008 mg/ml	?		Ranitidine hydrochloride : 0,05 mg/ml	48		210
		0,06 mg/ml	22°C		Dopamine hydrochloride : 5 mg/ml	24		3381
		0,06 mg/ml	22°C		Dobutamine hydrochloride : 5 mg/ml	24		3381
		0,06 mg/ml	22°C		Dobutamine hydrochloride : 5 mg/ml Amiodarone hydrochloride : 12,5 mg/ml	24		3381
		0,032 mg/ml	22-23°C		Piperacillin sodium / tazobactam : 20 / 2.5 mg/ml	24		4758
		0,032 mg/ml	22-23°C		Moxifloxacin : 8 mg/ml	24		4758



Facteur influençant la stabilité

























				1965
				197
				4160
	PH > 6			642
				197



Compatibilités

		Norepineprine bitartrate : 0,5 mg/ml Alprostadil : 20 µg/ml	4491
		Norepineprine bitartrate : 0,5 mg/ml Alprostadil : 20 µg/ml	4651
		Norepineprine bitartrate : 0,96 mg/ml Amiodarone hydrochloride : 15 mg/ml	3823
		Norepineprine bitartrate : 0,2 mg/ml Amiodarone hydrochloride : 12,5 mg/ml	4119
		Norepineprine bitartrate : 0,1 mg/ml Amiodarone hydrochloride : 12,5 mg/ml	4119
		Norepineprine bitartrate : 0,1 mg/ml Amiodarone hydrochloride : 25 mg/ml	4119
		Norepineprine bitartrate : 0,2 mg/ml Amiodarone hydrochloride : 25 mg/ml	4119
		Norepineprine bitartrate : 0,064 mg/ml Amiodarone hydrochloride : 4 mg/ml	1036
		Norepineprine bitartrate : 0,5 mg/ml Amiodarone hydrochloride : 0,6 >> 9,75 mg/ml	4119
		Norepineprine bitartrate : 0,5 mg/ml Amiodarone hydrochloride : 25 mg/ml	4119
		Norepineprine bitartrate : 0,2 mg/ml Amiodarone hydrochloride : 0,6 >> 9,75 mg/ml	4119
		Norepineprine bitartrate : 0,5 mg/ml Amiodarone hydrochloride : 12,5 mg/ml	4119
		Norepineprine bitartrate : 0,1 mg/ml Amiodarone hydrochloride : 0,6 >> 9,75 mg/ml	4119
		Norepineprine bitartrate Amobarbital sodium	642
		Norepineprine bitartrate : 1 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml	3824
		Norepineprine bitartrate : 1 mg/ml Argatroban : 1 mg/ml	1964
		Norepineprine bitartrate : 0,12 mg/ml Bivalirudin : 5 mg/ml	1713
		Norepineprine bitartrate : 1 mg/ml Caffeine : 10 mg/ml	3964

		Norepinephrine bitartrate Calcium gluconate		3644
		Norepinephrine bitartrate : 0,128 mg/ml Caspofungin acetate : 0,7 mg/ml		2247
		Norepinephrine bitartrate : 0.128 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Norepinephrine bitartrate : 0,128 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
		Norepinephrine bitartrate : 0,128 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Norepinephrine bitartrate : 0.128 mg/ml Ceftobiprole medocartil sodium : 2 mg/ml		2269
		Norepinephrine bitartrate : 0.128 mg/ml Ceftobiprole medocartil sodium : 2 mg/ml	RL	2269
		Norepinephrine bitartrate : 0.032 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Norepinephrine bitartrate Chlorothiazide sodium		642
		Norepinephrine bitartrate : 0.04 mg/ml Cimetidine hydrochloride : 3 mg/ml		1201
		Norepinephrine bitartrate : 0.064 mg/ml Ciprofloxacin lactate : 2 mg/ml		285
		Norepinephrine bitartrate : 0.12 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
		Norepinephrine bitartrate : 0,02 mg/ml Clonidine hydrochloride : 0,018 mg/ml		2018
		Norepinephrine bitartrate : 1 mg/ml Cloxacillin sodium : 100 mg/ml		3012
		Norepinephrine bitartrate : 0.12 mg/ml Dexmedetomidine : 4 µg/ml		1712
		Norepinephrine bitartrate : 0.128 mg/ml Diltiazem hydrochloride : 1 mg/ml		314
		Norepinephrine bitartrate : 0,12 mg/ml Diltiazem hydrochloride : 1 mg/ml		524
		Norepinephrine bitartrate : 0.32 mg/ml Dobutamine hydrochloride : 8 mg/ml		1506
		Norepinephrine bitartrate : 0.128 mg/ml Dobutamine hydrochloride : 4 mg/ml		314
		Norepinephrine bitartrate : 0.06 mg/ml Dobutamine hydrochloride : 5 mg/ml		3381
		Norepinephrine bitartrate : 0,06 mg/ml Dobutamine hydrochloride : 5 mg/ml		3177
		Norepinephrine bitartrate : 0.064 mg/ml Dobutamine hydrochloride : 2 mg/ml		1041
		Norepinephrine bitartrate : 0.96 mg/ml Dobutamine hydrochloride : 10 mg/ml		3823
		Norepinephrine bitartrate : 0.06 mg/ml Dobutamine hydrochloride : 5 mg/ml		2879
		Norepinephrine bitartrate : 0.32 mg/ml Dopamine hydrochloride : 8 mg/ml		1506
		Norepinephrine bitartrate : 0,06 mg/ml Dopamine hydrochloride : 5 mg/ml		3177

<input checked="" type="checkbox"/>	Norepinephrine bitartrate : 0.96 mg/ml Dopamine hydrochloride : 20 mg/ml		3823
<input checked="" type="checkbox"/>	Norepinephrine bitartrate : 0.064 mg/ml Dopamine hydrochloride : 3.2 mg/ml		295
<input checked="" type="checkbox"/>	Norepinephrine bitartrate : 0.128 mg/ml Dopamine hydrochloride : 3.2 mg/ml		314
<input checked="" type="checkbox"/>	Norepinephrine bitartrate : 0.06 mg/ml Dopamine hydrochloride : 5 mg/ml		2879
<input checked="" type="checkbox"/>	Norepinephrine bitartrate : 0,128 mg/ml Doripenem : 5 mg/ml		2262
<input checked="" type="checkbox"/>	Norepinephrine bitartrate : 0.128 mg/ml Epinephrine hydrochloride : 20 µg/ml		314
<input checked="" type="checkbox"/>	Norepinephrine bitartrate : 0,032 mg/ml Eravacycline : 0,6 mg/ml		4434
<input checked="" type="checkbox"/>	Norepinephrine bitartrate : 0.064 mg/ml Esmolol hydrochloride : 40 mg/ml		295
<input checked="" type="checkbox"/>	Norepinephrine bitartrate : 0.128 mg/ml Esmolol hydrochloride : 10 mg/ml		3879
<input checked="" type="checkbox"/>	Norepinephrine bitartrate : 0.004 mg/ml Famotidine : 0.2 mg/ml		398
<input checked="" type="checkbox"/>	Norepinephrine bitartrate : 0.12 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
<input checked="" type="checkbox"/>	Norepinephrine bitartrate : 0.32 mg/ml Fentanyl citrate : 30 µg/ml		1506
<input checked="" type="checkbox"/>	Norepinephrine bitartrate : 0.128 mg/ml Fentanyl citrate : 50 µg/ml		314
<input checked="" type="checkbox"/>	Norepinephrine bitartrate : 0.032 mg/ml Fosfomycin : 30 mg/ml		4055
<input checked="" type="checkbox"/>	Norepinephrine bitartrate : 0,016 mg/ml Furosemide : 1 mg/ml		4570
<input checked="" type="checkbox"/>	Norepinephrine bitartrate : 0.128 mg/ml Furosemide : 10 mg/ml		314
<input checked="" type="checkbox"/>	Norepinephrine bitartrate : 0,016 mg/ml Furosemide : 10 mg/ml		4570
<input checked="" type="checkbox"/>	Norepinephrine bitartrate : 0.032 mg/ml Haloperidol lactate : 0.5 & 5 mg/ml		403
<input checked="" type="checkbox"/>	Norepinephrine bitartrate : 0.12 mg/ml Hetastarch : 60 mg/ml		1721
	<input checked="" type="checkbox"/> Norepinephrine bitartrate		642
<input checked="" type="checkbox"/>	Norepinephrine bitartrate : 0.016 mg/ml		301
<input checked="" type="checkbox"/>	Norepinephrine bitartrate : 1 mg/ml		3948
<input checked="" type="checkbox"/>	Norepinephrine bitartrate : 0,1 mg/ml Furosemide : 1 mg/ml		4570
<input checked="" type="checkbox"/>	Norepinephrine bitartrate : 0,1 mg/ml Furosemide : 10 mg/ml		4570
<input checked="" type="checkbox"/>	Norepinephrine bitartrate : 0.1 mg/ml Furosemide : 10 mg/ml		3210
<input checked="" type="checkbox"/>	Norepinephrine bitartrate : 0,128 mg/ml Hydrocortisone sodium succinate : 1 mg/ml		4465
<input checked="" type="checkbox"/>	Norepinephrine bitartrate : 1 mg/ml		3948

	Norepinephrine bitartrate : 0.128 mg/ml Heparin sodium : 100 UI/ml		314
	Norepinephrine bitartrate : 0.128 mg/ml Hydromorphone hydrochloride : 1 mg/ml		314
	Norepinephrine bitartrate : 0.00027 mg/ml		1338
	Norepinephrine bitartrate : 0.32 mg/ml Insulin : 1 UI/ml		1506
	Norepinephrine bitartrate : 1 mg/ml	RL	4603
	Norepinephrine bitartrate : 0,032 mg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433
			295
	Norepinephrine bitartrate : 0,12 mg/ml Insulin aspart : 1 UI/ml		1508
	Norepinephrine bitartrate : 0.032 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
	Norepinephrine bitartrate : 1 mg/ml Ketamine hydrochloride : 50 mg/ml		4389
	Norepinephrine bitartrate : 0.064 mg/ml Labetalol hydrochloride : 5 mg/ml		295
	Norepinephrine bitartrate : 0.128 mg/ml Labetalol hydrochloride : 5 mg/ml		3879
	Norepinephrine bitartrate : 0,016 mg/ml	Normo Sol®	4655
	Norepinephrine bitartrate : 0.128 mg/ml Labetalol hydrochloride : 2 mg/ml		314
	Norepinephrine bitartrate : 0,016 >>0,064 mg/ml Levetiracetam : 5 mg/ml		4569
	Norepinephrine bitartrate : 0,064 mg/ml Levofloxacin : 5 mg/ml		3865
	Norepinephrine bitartrate : 0.128 mg/ml Lorazepam : 0.5 mg/ml		314
			3838
	Norepinephrine bitartrate : 1 mg/ml Meropenem : 50 mg/ml		4319
	Norepinephrine bitartrate : 8 mg/ml Meropenem : 1 & 20 mg/ml		266
	Norepinephrine bitartrate : 1 mg/ml Meropenem : 1 & 50 mg/ml		266
	Norepinephrine bitartrate : 0.32 mg/ml Methadone hydrochloride : 0.2 mg/ml		1506
	Norepinephrine bitartrate : 0.128 mg/ml Metoprolol tartrate : 0.4 mg/ml		3879
	Norepinephrine bitartrate : 0.128 mg/ml Miconazole : 1.5 mg/ml		2108
	Norepinephrine bitartrate : 0.064 mg/ml Midazolam hydrochloride : 1 mg/ml		295
	Norepinephrine bitartrate : 0.32 mg/ml Midazolam hydrochloride : 4 mg/ml		1506
	Norepinephrine bitartrate : 0.128 mg/ml Midazolam hydrochloride : 2 mg/ml		314

	Norepinephrine bitartrate : 0.128 mg/ml Milrinone lactate : 0.2 mg/ml		314
	Norepinephrine bitartrate : 0.128 mg/ml Milrinone lactate : 0.8 mg/ml		813
	Norepinephrine bitartrate : 0,032 mg/ml Milrinone lactate : 1 mg/ml		4506
	Norepinephrine bitartrate : 0.32 mg/ml Morphine hydrochloride : 1 mg/ml		1506
	Norepinephrine bitartrate : 0.064 mg/ml Morphine sulfate : 1 mg/ml		295
	Norepinephrine bitartrate : 0.128 mg/ml Morphine sulfate : 2 mg/ml		314
	Norepinephrine bitartrate : 0,064 mg/ml Moxifloxacin : 1,6 mg/ml		3865
	Norepinephrine bitartrate : 1 mg/ml Mycophenolate mofetil : 5,9 mg/ml		2192
	Norepinephrine bitartrate : 1 mg/ml N-acetylcysteine : 200 mg/ml		3766
	Norepinephrine bitartrate : 1 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408
	Norepinephrine bitartrate : 0.064 mg/ml Netilmicin sulfate : 3 mg/ml		1200
	Norepinephrine bitartrate : 0.128 mg/ml Nicardipine hydrochloride : 1 mg/ml		314
	Norepinephrine bitartrate : 0.128 mg/ml Nitroglycerin : 0.4 mg/ml		314
	Norepinephrine bitartrate : 0.12 mg/ml Oritavancin : 0.8 >>2 mg/ml		3152
	Norepinephrine bitartrate : > 0.064 mg/ml Pantoprazole sodium : > 0.8 mg/ml		1902
	Norepinephrine bitartrate : < 0.064 mg/ml Pantoprazole sodium : < 0.1 mg/ml		1902
	Norepinephrine bitartrate Pantoprazole sodium		2090
	Norepinephrine bitartrate : < 0.013 mg/ml Pantoprazole sodium : < 0.8 mg/ml		1902
	Norepinephrine bitartrate : 1 mg/ml Paracetamol : 10 mg/ml		4742
	Norepinephrine bitartrate Pentobarbital sodium		642
	Norepinephrine bitartrate : 5 mg/ml Pentoxifyllin : 5 mg/ml		4543
	Norepinephrine bitartrate Phenobarbital sodium		642
	Norepinephrine bitartrate Phenytoin sodium		642
	Norepinephrine bitartrate : 0.032 mg/ml Plazomicin sulfate : 24 mg/ml		4145
	Norepinephrine bitartrate Posaconazole		4380
	Norepinephrine bitartrate : 1 mg/ml Propofol		4524

	Norepinephrine bitartrate : 0.016 mg/ml Propofol : 10 mg/ml	∅	300
	Norepinephrine bitartrate : 4 & 8 mg/ml Ranitidine hydrochloride : 0.05 & 2 mg/ml		214
	Norepinephrine bitartrate : 0.128 mg/ml Ranitidine hydrochloride : 1 mg/ml		314
	Norepinephrine bitartrate : 0.004 & 0.008 mg/ml Ranitidine hydrochloride : 0.05 & 2 mg/ml		210
	Norepinephrine bitartrate : 0.12 mg/ml Remifentanyl hydrochloride : 25 & 250 µg/ml		59
	Norepinephrine bitartrate : 1 mg/ml Salbutamol sulfate : 1 mg/ml	∅	3216
	Norepinephrine bitartrate Sodium bicarbonate		642
	Norepinephrine bitartrate Streptomycin sulfate		642
	Norepinephrine bitartrate : 1 mg/ml Sufentanyl citrate : 0,05 mg/ml		4389
	Norepinephrine bitartrate : 1 mg/ml Sugammadex : 100 mg/ml	∅	3372
	Norepinephrine bitartrate : 0,03 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
	Norepinephrine bitartrate : 0.032 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
	Norepinephrine bitartrate : 0.128 mg/ml Telavancin hydrochloride : 7.5 mg/ml		3254
	Norepinephrine bitartrate : 0.128 mg/ml Telavancin hydrochloride : 7.5 mg/ml	RL	3254
	Norepinephrine bitartrate : 1 mg/ml Thiopental sodium : 25 mg/ml		3767
	Norepinephrine bitartrate : 0.128 mg/ml Thiopental sodium : 25 mg/ml		642
	Norepinephrine bitartrate : 0,128 mg/ml Thiopental sodium : 25 mg/ml		314
	Norepinephrine bitartrate Tigecycline		3332
	Norepinephrine bitartrate : 0.004 & 0.016 mg/ml Vasopressin : 0.2 UI/ml		2017
	Norepinephrine bitartrate : 0.004 mg/ml Vasopressin : 2 & 4 UI/ml		1801
	Norepinephrine bitartrate : 0.128 mg/ml Vecuronium bromide : 1 mg/ml		314
	Norepinephrine bitartrate : 0.008 mg/ml Verapamil hydrochloride : 0.08 mg/ml		1057



Voie d'administration



Bibliographie

	Type	Source
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
192	Revue	Peddicord TE, Olsen KM, ZumBrunnen TL, Warner DJ, Webb L. Stability of high-concentration dopamine hydrochloride, norepinephrine bitartrate, epinephrine hydrochloride, and nitroglycerin in 5% dextrose injection. Am J Health-Syst Pharm 1997 ; 54: 1417-1419.
197	Revue	Allwood MC. The stability of four catecholamines in 5% glucose infusions. J Clin Pharm Ther 1991 ; 16: 337-340.
210	Revue	Stewart JT, Warren FW, King AD. Stability of ranitidine hydrochloride and seven medications. Am J Hosp Pharm 1994 ; 51: 1802-1807.
214	Revue	Galante LJ, Stewart JT, Warren FW, Edgar JW, Huff AJ. Stability of ranitidine hydrochloride with eight medications in intravenous admixtures. Am J Hosp Pharm 1990 ; 47: 1606-1610.
266	Revue	Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
285	Revue	Elmore RL, Contois ME, Kelly J, Noe A, Poirier A. Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. Clin Ther 1996 ; 18: 246-255.
295	Revue	Yamashita SK, Walker SE, Choudhury T, Iazzetta J. Compatibility of selected critical care drugs during Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1048-1051.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
314	Revue	Chiu MF, Schwartz ML. Visual compatibility of injectable drugs used in the intensive care unit. Am J Health-Syst Pharm 1997 ; 54: 64-65.
398	Revue	Jay GT, Fanikos J, Souney PF. Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1556-1557.

403	Revue	Outman WR, Monolakis J. Visual compatibility of haloperidol lactate with 0.9% sodium chloride injection or injectable critical-care drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 1539-1541.
524	Revue	Farquhar Zanetti LA. Visual compatibility of diltiazem with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1992 ; 49: 1911.
642	Revue	Baumgartner TG, Knudsen AK, Dunn AJ, Kilroy RA. Norepinephrine stability in saline solutions. Hosp Pharm 1988 ; 23: 44,49, 59.
813	Revue	Akkermann SR, Zhang H, Mullins RE, Yaughn K. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions. Am J Health-Syst Pharm 1999 ; 56: 63-68.
1036	Revue	Hasegawa GR, Eder JF. Visual compatibility of amiodarone hydrochloride injection with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 1379-1380.
1041	Revue	Hasegawa GR, Eder JF. Visual compatibility of dobutamine hydrochloride with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 949-951.
1057	Revue	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1200	Revue	Chaudry IA, Bruey KP, Hurlburt LE, Oden EM. Compatibility of netilmycin sulfate injection with commonly used intravenous injections and additives. Am J Hosp Pharm 1981 ; 38: 1737-1742.
1201	Revue	Yuhas EM, Lofton FT, Rosenberg HA, Mayron D, Balduin JG. Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures. Am J Hosp Pharm 1981 ; 38: 1919-1922.
1338	Revue	Baptista RJ, Dumas GJ, Bistran BR, Condella F, Blackburn GL. Compatibility of total nutrient admixtures and secondary cardiovascular medications. Am J Hosp Pharm 1985 ; 42: 777-778.
1506	Revue	Lopez-Cabezas C, Guerrero L, Molas G, Anglada H, Soy D. Physicochemical compatibility of high concentration drugs usually Y-site administered in intensive care units. EJHP 2015 ;22:107-112.
1508	Revue	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1801	Revue	Feddema S, Rusho WJ, Tyler LS, Barker B. Physical compatibility of vasopressin with medications commonly used in cardiac arrest. Am J Health-Syst Pharm 2003 ; 60: 1271-1272.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.

1902	Revue	Walker SE, Wyllie A, Law S. Physical compatibility of pantoprazole with selected medications during simulated Y-site administration. Can J Hosp Pharm 2004 ; 57, 2: 90-96.
1964	Revue	Hartman CA, Baroletti SA, Churchill WW et al. Visual compatibility of argatroban with selected drugs. Am J Health-Syst Pharm 2002 ; 59: 1784-1785.
1965	Revue	Brustugun J, Kristensen S, Tonnesen HH. Photostability of sympatomimetic agents in commonly used infusion media in the absence and presence of bisulfite. PDA J Pharm Sci Technol 2004 ; 58, 6: 296-308.
2017	Revue	Barker B, Feddema S, Rusho WJ, Dengg R. Visual compatibility of vasopressin with other injectable drugs. Am J Health-Syst Pharm 2005 ; 62: 1969-1976.
2018	Revue	Veggeland T. Visual compatibility of clonidine with selected drugs. Am J Health-Syst Pharm 2005 ; 62: 1968-1969.
2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2108	Revue	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2192	Revue	Cochran BG, Sowinski KM, Fausel C, Overholser BR. Physical compatibility and chemical stability of mycophenolate mofetil during simulated Y-site administration with commonly coadministered drugs. Am J Health-Syst Pharm 2007 ; 64, 13: 1410-1414.
2247	Revue	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2879	Poster	Imesch G., Humbert-Delaloye V., Berger M., Pannatier A. Compatibilité entre amiodarone, catecholamines et/ou nitroprussiate de sodium, administré en continu par voie veineuse aux soins intensifs adultes. GSASA Congress - Lucerne - Switzerland 2008
3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3111	Revue	Walker SE, Law S, Garland J, Fung E, Iazzetta J. Stability of Norepinephrine Solutions in Normal Saline and 5% Dextrose in Water. Can J Hosp Pharm 2010 ; 63, 2: 113-118.
3152	Revue	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3177	Poster	Humbert-Delaloye V, Berger M, Pannatier A. Compatibilités physico-chimique entre catécholamines, amiodarone, et/ou nitroprussiate de sodium intraveineux. 16èmes JFSPH, Sion, 18-19 novembre 2010 2010

3210	Revue	Jasti Bhaskara R, Saraf Poonam. Compatibility of Parenteral Furosemide with Seventeen Secondary Drugs Used in Standard Concentrations. Int J Pharm Compound 2011 ; 15, 3: 259-261.
3216	Revue	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	Revue	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	Revue	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332	Laboratoire	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3346	Revue	H?llein L, Bennack E, Holzgrabe U. Stabilität, Qualität und Analytik individueller Noradrenalin-Zubereitungen. Krankenhauspharmazie 2012 ; 33: 427-431.
3372	Revue	Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S. Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. Rev Bras Anesthesiol 2013 ; 63, 1: 163-166.
3381	Revue	Humbert-Delaloye V, Berger-Gryllaki M, Voirol P, Gattlen L, Pannatier A. In vitro compatibility of various cardioactive drugs during simulated Y-site administration. EJHP 2013 ; 20:110-116.
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3644	Laboratoire	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3766	Revue	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	Revue	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3823	Revue	Juan E.P, Palau M.M, Cerd? S.A, Rubert M.A, Nicolau B.R. Compatibilité physique de médicaments administrés dans l'unité de soins intensifs Pharmactuel 2015 ; 48, 3 : 146-152.
3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftazolidime/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavanazonium sulfate during simulated Y-site administration. ASHP Midyear 2015

3838	Laboratoire	Magnesium Sulphate - Summary of Product Characteristics Martindale Pharmaceuticals Ltd 2007
3865	Revue	Vicky M, Samit S, Jaymin P, Michael C T. Compatibility of Norepinephrine Bitartrate with Levofloxacin and Moxifloxacin During Simulated Y-site Administration. Int J Pharm Compound 2016 ; 20, 3 : 236-238.
3879	Revue	Foushee Jaime A, Meredith Pmichalee, Fox Laura M, Grace Edward E. Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures. Int J Pharm Compound 2016 ; 20, 4 : 328-332.
3948	Revue	Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P . Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation. JPEN 2012 ;30. 416?424.
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilit� du citrate de caf�ine injectable avec plusieurs autres m�dicaments. Pharmactuel 2017 ; 50,1 : 27-33.
3989	Revue	Feutry F, Genay S, Velghe C, Barth�l�my C, D�caudin B, Odou, P. Stability of midazolam and noradrenaline stored in cyclic olefin copolymer AT-Closed Vials® and polypropylene syringes during 365 days. Pharmaceutical Technology in Hospital Pharmacy 2017 ; 2,1: 35
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4119	Poster	Marcoz N, Ing H, Sautter AM, Saadi JF, Roulin JF, Bonnabry P. Stabilit� et compatibilit� de solutions injectables d'amiodarone (Cordarone®) H�pitaux Universitaire de Gen�ve 2004
4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4160	Revue	West G.B. The Stability of Noradrenaline Solutions. J Pharm Pharmacol 1952 560-565
4250	Revue	D'Huart E, Vigneron J, Clarot I, Demor� B. Physicochemical stability of norepinephrine bitartrate in polypropylene syringes at high concentrations for intensive care units. Ann Pharm Fr 2019 ;77,3:212-221.
4319	Revue	Lessard J-J, Caron E, Sch�rer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4323	Poster	Wethmar U, Hochbr�gge H, Strobel HG. Stabilit�spr�fung von applikationsfertigen Adrenalin- und Noradrenalinverd�nnungen. ADKA Kongress 2019
4380	Laboratoire	Posaconazole (Noxafil®) - Summary of Product Characteristics Merck Sharp & Dohme Limited 2019
4389	Revue	C�t� K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilit� physique des m�dicaments administr�s en Y aux soins intensifs, en particulier la dexm�d�tomidine, le l�vosimendan et la k�tamine. Pharmactuel 2019 ;52,4:206-213
4433	Revue	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.

4434	Revue	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4465	Revue	Foushee A, Meredith P, Fox Laura, Wilder A. Y-site physical compatibility of hydrocortisone continuous infusions with admixtures used in critically ill patients. Am J Health-Syst Pharm 2020 ;77,14:1144-1148
4491	Revue	De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pilar P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pedia 2020
4506	Revue	Griffith S, Stapleton E, Padilla S, Mruk A, Thomas C. Physical compatibility of milrinone 1 mg/mL with select cardiovascular medications during simulated Y-site administration. Am J Health-Syst Pharm 2020 ;77,23:1938-1940.
4524	Poster	Stucki C, Sautter A-M, Bonnabry P. Physical compatibility of the propofol emulsion with 33 drugs used in anaesthesiology. ESCP Symposium, Geneva, Switzerland 2009
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4543	Revue	Senarathna G, Strunk T, Petrovski M, Batty K. Physical compatibility of pentoxifylline and intravenous medications. Archives of Disease in Childhood 2018 ;104:292–295.
4569	Revue	Lee T.M , Villareal C.L, Meyer L.M. Y-Site Compatibility of Intravenous Levetiracetam With Commonly Used Critical Care Medications. Hosp Pharm 2021 ; 56, 4: 282-286.
4570	Revue	Greenhill K, Hornsby E, Gorman G. Investigations of Physical Compatibilities of Commonly Used Intravenous Medications with and without Parenteral Nutrition in Pediatric Cardiovascular Intensive Care Unit Patients. Pharmaceuticals 2019
4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4651	Revue	De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pascual P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pedia 2021 ;180,1169–1176.
4655	Revue	Holyk A, Lindner A, Lindner S, Shippert B Physical compatibility of Normosol-R with critical care medications used in patients with COVID-19 during simulated Y-site administration. Am J Health-Syst Pharm 2022 ;79,1:27-33
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4758	Revue	Schmidt J.P, Steppe M. Stability Study and Simultaneous Determination of Norepinephrine, Moxifloxacin, and Piperacillin + Tazobactam Mixtures Applied in Intensive Care Medicine . Curr Pharm Anal 2023 ; 19, 4: 307-316.
4801	Revue	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:



Dictionnaire

	Sympathomimétique		Injectable
	Noms commerciaux		Stabilité des solutions
	Contenant		Molécule
	Concentration		Température
	Conservation		Durée de stabilité
	Biosimilaire		Données conflictuelles
	Bibliographie		Polyvinyl chlorure
	NaCl 0,9% ou glucose 5%		Lumière
	Heure		A l'abri de la lumière
	Jour		Glucose 5%
	Seringue polypropylène		Chlorure de sodium 0,9%
	Avec ou sans lumière		AT-Closed vial®
	Non précisé		Stabilité en mélange
	Solvant		Molécule
	Verre		Non précisée
	Polyéthylène		Polypropylène
	NaCl 0,45% Glucose 2,5%		Facteur influençant la stabilité
	Provoque		Dégradation
	Augmentation stabilité		NaHCO3
	Compatibilités		Précipitation en 4 heures
	Incompatible		Compatible
	Turbidité immédiate		Incompatibilité non précisée
	Aucun		Ringer lactate
	Eau pour préparation injectable		Solvant spécifique
	Nutrition parentérale (mélange binaire)		Nutrition parentérale (mélange ternaire)
	Précipitation immédiate		Normosol®
	Précipitation en 15 minutes		Voie d'administration
	Intraveineuse		Perfusion intraveineuse
	Intracardiaque		Bibliographie
	Dictionnaire		